MA50752B1 - Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation - Google Patents

Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation

Info

Publication number
MA50752B1
MA50752B1 MA50752A MA50752A MA50752B1 MA 50752 B1 MA50752 B1 MA 50752B1 MA 50752 A MA50752 A MA 50752A MA 50752 A MA50752 A MA 50752A MA 50752 B1 MA50752 B1 MA 50752B1
Authority
MA
Morocco
Prior art keywords
methods
drug conjugates
antibody drug
activatable antibody
antibodies
Prior art date
Application number
MA50752A
Other languages
English (en)
Other versions
MA50752A (fr
Inventor
Jonathan Alexander Terrett
Shweta Singh
Jennifer Hope Richardson
Laura Patterson Serwer
Susan E Morgan-Lappe
Tracy Henriques
Sherry L Ralston
Marvin Robert Leanna
Ilaria Badagnani
Sahana Bose
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MA50752A publication Critical patent/MA50752A/fr
Publication of MA50752B1 publication Critical patent/MA50752B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne d'une manière générale des anticorps qui se lient spécifiquement à cd71 dans leur forme active et des procédés de réalisation et d'utilisation de ces anticorps anti-cd711 activables conjugués dans une variété d'indications thérapeutiques, diagnostiques et prophylactiques.
MA50752A 2017-10-14 2018-10-12 Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation MA50752B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762572467P 2017-10-14 2017-10-14
PCT/US2018/055733 WO2019075417A1 (fr) 2017-10-14 2018-10-12 Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA50752A MA50752A (fr) 2020-08-12
MA50752B1 true MA50752B1 (fr) 2021-03-31

Family

ID=64110112

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50752A MA50752B1 (fr) 2017-10-14 2018-10-12 Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation

Country Status (36)

Country Link
US (3) US20190111150A1 (fr)
EP (2) EP3834846A1 (fr)
JP (2) JP7374891B2 (fr)
KR (4) KR20230070046A (fr)
CN (1) CN111278467B (fr)
AR (1) AR115178A1 (fr)
AU (1) AU2018346969A1 (fr)
BR (1) BR112020007302B1 (fr)
CA (1) CA3077730A1 (fr)
CL (1) CL2020000977A1 (fr)
CO (1) CO2020005685A2 (fr)
CR (1) CR20200206A (fr)
CY (1) CY1123968T1 (fr)
DK (1) DK3691692T3 (fr)
DO (1) DOP2023000150A (fr)
EC (1) ECSP20025198A (fr)
ES (1) ES2864013T3 (fr)
HR (1) HRP20210436T8 (fr)
HU (1) HUE054037T2 (fr)
IL (1) IL273586A (fr)
LT (1) LT3691692T (fr)
MA (1) MA50752B1 (fr)
MD (1) MD3691692T2 (fr)
MX (1) MX2020003723A (fr)
PE (1) PE20210125A1 (fr)
PH (1) PH12020550417A1 (fr)
PL (1) PL3691692T3 (fr)
PT (1) PT3691692T (fr)
RS (1) RS61596B1 (fr)
RU (2) RU2022111211A (fr)
SG (1) SG11202003378WA (fr)
SI (1) SI3691692T1 (fr)
SM (1) SMT202100184T1 (fr)
TW (2) TW202330039A (fr)
UY (1) UY37931A (fr)
WO (1) WO2019075417A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
TWI787796B (zh) 2015-05-04 2022-12-21 美商Ｃｙｔｏｍｘ生物製藥公司 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
AU2018281280B2 (en) 2017-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
PE20210125A1 (es) * 2017-10-14 2021-01-19 Abbvie Inc Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
WO2019183633A1 (fr) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Composés conjugués ciblés sur le psma et leurs utilisations
EP3793591A1 (fr) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anticorps anti-cd63, conjugués et leurs utilisations
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
KR20220164773A (ko) * 2020-04-08 2022-12-13 앨리어다 테라퓨틱스, 인코포레이티드 혈액-뇌 장벽 전달용 조성물 및 방법
WO2021207657A1 (fr) * 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions contenant des anticorps activables
AU2021313058A1 (en) * 2020-07-23 2023-03-30 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
CA3226298A1 (fr) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Complexes de ciblage musculaire et leurs utilisations dans le traitement de dystrophinopathies
EP4366774A4 (fr) * 2021-07-09 2025-11-19 Dyne Therapeutics Inc Complexes de ciblage musculaire et leurs utilisations pour la modulation de gènes associés à la santé musculaire
US20250332265A1 (en) 2021-11-09 2025-10-30 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
CN120659627A (zh) * 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법
WO2025133132A1 (fr) * 2023-12-20 2025-06-26 Institut National De La Sante Et De La Recherche Medicale Nouveaux anticorps anti-tfr1 (cd71) pour le traitement du cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
WO2007027935A2 (fr) 2005-08-31 2007-03-08 The Regents Of The University Of California Bibliotheques cellulaires de sequences peptidiques (clips) et procedes d'utilisation de celles-ci
EP2190861A4 (fr) 2007-08-22 2011-03-30 Univ California Polypeptides de liaison activables et procédés d'identification et utilisation de ceux-ci
US8236318B2 (en) * 2007-11-07 2012-08-07 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP3543256A1 (fr) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Compositions d anticorps modifiées et leurs procédés de production et d'utilisation
ES2725356T3 (es) * 2009-04-29 2019-09-23 Henry M Jackson Found Advancement Military Medicine Inc Anticuerpos monoclonales de ERG2 y su uso terapéutico
WO2010129609A2 (fr) 2009-05-07 2010-11-11 The Regents Of The University Of California Anticorps et procédés d'utilisation de ceux-ci
SG191977A1 (en) * 2011-02-01 2013-08-30 Genmab As Human antibodies and antibody-drug conjugates against cd74
HUE054362T2 (hu) * 2012-01-31 2021-09-28 Sbi Biotech Co Ltd Foszfolipáz D4 elleni antitest
EP2882844B1 (fr) 2012-08-10 2018-10-03 Cytomx Therapeutics Inc. Systèmes résistant aux protéases pour présentation de polypeptides, leurs procédés de préparation et utilisation
CN103145847B (zh) * 2013-02-05 2014-05-21 浙江大学 一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
TWI787796B (zh) 2015-05-04 2022-12-21 美商Ｃｙｔｏｍｘ生物製藥公司 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
CN106237341B (zh) * 2016-07-12 2019-07-30 浙江大学 一种抗体偶联药物及其制备方法和应用
PE20210125A1 (es) * 2017-10-14 2021-01-19 Abbvie Inc Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos

Also Published As

Publication number Publication date
PT3691692T (pt) 2021-03-29
TWI780237B (zh) 2022-10-11
US20240115724A1 (en) 2024-04-11
CO2020005685A2 (es) 2020-05-15
KR102529359B1 (ko) 2023-05-09
JP7374891B2 (ja) 2023-11-07
RS61596B1 (sr) 2021-04-29
ES2864013T3 (es) 2021-10-13
CA3077730A1 (fr) 2019-04-18
HUE054037T2 (hu) 2021-08-30
US20210145978A1 (en) 2021-05-20
EP3691692B8 (fr) 2021-05-26
CR20200206A (es) 2021-02-18
PH12020550417A1 (en) 2021-04-12
HRP20210436T8 (hr) 2022-01-07
KR20200070324A (ko) 2020-06-17
WO2019075417A1 (fr) 2019-04-18
KR20230004932A (ko) 2023-01-06
CN111278467B (zh) 2024-07-30
DOP2023000150A (es) 2023-08-31
DK3691692T3 (da) 2021-03-22
RU2022111211A (ru) 2022-05-05
CY1123968T1 (el) 2022-05-27
MX2020003723A (es) 2020-07-22
BR112020007302B1 (pt) 2023-01-31
PL3691692T3 (pl) 2021-07-19
EP3691692B1 (fr) 2020-12-30
TW202330039A (zh) 2023-08-01
CL2020000977A1 (es) 2020-09-11
MD3691692T2 (ro) 2021-05-31
CN111278467A (zh) 2020-06-12
MA50752A (fr) 2020-08-12
IL273586A (en) 2020-05-31
KR20230070046A (ko) 2023-05-19
PE20210125A1 (es) 2021-01-19
SG11202003378WA (en) 2020-05-28
US20190111150A1 (en) 2019-04-18
ECSP20025198A (es) 2020-06-30
RU2020115713A3 (fr) 2022-02-25
JP2020537649A (ja) 2020-12-24
KR20220045088A (ko) 2022-04-12
TW201927815A (zh) 2019-07-16
SMT202100184T1 (it) 2021-05-07
RU2771292C2 (ru) 2022-04-29
AR115178A1 (es) 2020-12-09
AU2018346969A1 (en) 2020-04-23
SI3691692T1 (sl) 2021-04-30
RU2020115713A (ru) 2021-11-16
EP3691692A1 (fr) 2020-08-12
JP2024012366A (ja) 2024-01-30
LT3691692T (lt) 2021-05-10
HRP20210436T1 (hr) 2021-04-30
BR112020007302A2 (pt) 2020-09-29
KR102385495B1 (ko) 2022-04-15
EP3834846A1 (fr) 2021-06-16
UY37931A (es) 2019-04-30

Similar Documents

Publication Publication Date Title
MA50752A (fr) Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation
MA30345B1 (fr) Formulation d'anticorps monoclonal humain anti-igf-1r
MA39909B1 (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
CR20120505A (es) Composición de fármaco conjugado
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
WO2019014328A3 (fr) Anticorps agonistes qui lient cd137 humain et leurs utilisations
CL2019002250A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520)
MA32899B1 (fr) Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
EP3824096A4 (fr) Nouveaux anticorps et leurs procédés de préparation et d'utilisation
EP3783025A4 (fr) Anticorps cd73 ciblé et conjugué anticorps-médicament, procédé de préparation associé et utilisations correspondantes
MA30910B1 (fr) Anticorps et immunoconjugues, et leurs utilisations
EP3476399A4 (fr) Anticorps anti-lag-3, fragment de celui-ci se liant à l'antigène, et son application pharmaceutique
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
MA40041B1 (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA40671A1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MA43345A (fr) Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
CR8317A (es) Anticuerpos dirigidos a m-csf
CR11399A (es) ANTICUERPOS ANTI-IL-12/23p40, EPITOPES, FORMULACIONES, COMPOSICIONES, METODOS Y USOS
MA31984B1 (fr) Formulation d'anticorps
ATE391174T1 (de) Modifizierter tpo-agonisten antikörper
EP3941946A4 (fr) Anticorps anti-claudine-6 et conjugués de médicaments
JOP20190155A1 (ar) مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
MA31793B1 (fr) Nouveaux anticorps specifiques de peptides beta- amyloides et leurs utilisations comme agents diagnostiques ou medicaments